Zhangzhou Pientzehuang Pharmaceutical Co., Ltd., a prominent player in the health care sector, has been making significant strides in the pharmaceutical industry. Based in Zhangzhou, China, the company is renowned for its specialization in the manufacturing and marketing of traditional Chinese medications. Among its diverse product range, Pientzehuang, Pientzehuang capsules, Pientzehuang lozenges, and cough syrup stand out as flagship offerings. These products underscore the company’s commitment to integrating traditional Chinese medicine with modern pharmaceutical practices.
As of August 18, 2026, Zhangzhou Pientzehuang Pharmaceutical’s stock closed at 127.3 CNY on the Shanghai Stock Exchange, where it is publicly traded. The company’s market capitalization stands at a substantial 76.8 billion CNY, reflecting its robust presence in the market. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of 215.02 CNY on August 21, 2025, and a low of 105.98 CNY on June 28, 2026. These figures highlight the dynamic nature of the pharmaceutical sector and the company’s resilience in navigating market challenges.
The company’s financial metrics reveal a price-to-earnings ratio of 40.75, indicating investor confidence in its growth potential and profitability. This ratio, while relatively high, suggests that the market anticipates continued expansion and success in its operations.
Zhangzhou Pientzehuang Pharmaceutical’s journey began with its Initial Public Offering (IPO) on May 30, 2003. Since then, the company has established itself as a leader in the traditional Chinese medicine market, leveraging its rich heritage and innovative approaches to healthcare solutions. Its website, www.zzpzh.com , serves as a portal for stakeholders to access information about its products, corporate values, and market performance.
In summary, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. continues to be a significant entity in the health care sector, particularly within the pharmaceutical industry. Its focus on traditional Chinese medications, coupled with a strong market presence and financial stability, positions it well for future growth and innovation.
